Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma.
Bohl SR, Schmalbrock LK, Bauhuf I, Meyer T, Dolnik A, Szyska M, Blätte TJ, Knödler S, Röhner L, Miller D, Kull M, Langer C, Döhner H, Letai A, Damm F, Heckl D, Bullinger L, Krönke J.
Bohl SR, et al. Among authors: szyska m.
Blood Adv. 2021 May 11;5(9):2391-2402. doi: 10.1182/bloodadvances.2020003541.
Blood Adv. 2021.
PMID: 33950175
Free PMC article.